LEO Pharma A/S, a Denmark-based global leader in medical dermatology, announced it has appointed Brian Hilberdink new executive vice president and president of Madison-based LEO Pharma Inc. in the United States, effective March 14. Brian Hilberdink joins LEO Pharma from Novo Nordisk, Inc., in the U.S. where he served as Senior Vice President of Sales.
“We are excited to soon have an accomplished executive like Brian Hilberdink, with more than 25 years of global experience developing and executing strategy, leading our U.S. operation. With the recent FDA approval of our first biologic, and Brian at the helm, LEO Pharma stands to strongly deliver on our growth strategy in the world’s largest pharmaceutical market,” said Anders Kronborg, chief financial officer and acting chief executive officer of LEO Pharma.
Prior to joining Novo Nordisk in the U.S. as a senior vice president, Brian Hilberdink served as president of Novo Nordisk Canada Inc. and corporate vice president in Global Marketing of Novo Nordisk A/S in Denmark. In that role, he led the launch of the company’s next generation insulin portfolio.
“LEO Pharma has an exciting future, and I am thrilled to have the opportunity to lead the company’s growth journey in the U.S. Joining a company with such a history, which is going through a remarkable transformation and also expecting to go public feels like joining a 100-year-old start-up. It is a once in a lifetime opportunity that I wouldn’t miss,” said Brian Hilberdink.
Brian Hilberdink holds a bachelor’s degree from the Arts & Science faculty at Queen’s University in Canada and has completed extensive executive education at multiple universities.
To access more business news, visit NJB News Now.Related Articles: